|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1. Association between ASA and NSAID use and prostate cancer risk or disease grade vs. non-use stratified by treatment arm** | | | | | | | | | | | | | | | | | | |
|  | **Non-users** | |  | **ASA users** | | | |  | **NSAID users** | | |  | **ASA and NSAID users** | | | | | |
| **Variable** |  | |  | **OR** | **95% CI** | | **P** |  | **OR** | **95%CI** | **P** |  | **OR** | | | **95% CI** | | **P** |
| **Placebo Arm** | | | | | | | | | | | | | | | | | | |
| **Overall prostate cancer risk** | |  |  |  | |  | |  |  | | | | |  |  | |  |  |
| No. with cancer/total | | 429/1,626 | 157/676 | | | |  | 144/598 | | |  | 85/351 | | | | |  |
| Univariable | | Referent | 0.84 | 0.68-1.04 | | 0.11 |  | 0.89 | 0.71-1.10 | 0.27 |  | 0.89 | | | 0.68-1.17 | | 0.40 |
| Multivariable\* | | Referent | 0.80 | 0.63-1.01 | | 0.06 |  | 0.95 | 0.76-1.18 | 0.62 |  | 0.91 | | | 0.68-1.22 | | 0.54 |
| **Disease grade, low grade** | |  |  |  | |  |  |  | |  | |  | | |  | |  |
| No. with cancer/total\*\* | | 307/1,504 | 115/634 | | | |  | 102/556 | | |  | 65/331 | | | | |  |
| Univariable | | Referent | 0.86 | 0.68-1.10 | | 0.23 |  | 0.88 | 0.68-1.12 | 0.30 |  | 0.95 | | | 0.71-1.29 | | 0.75 |
| Multivariable\* | | Referent | 0.85 | 0.66-1.11 | | 0.24 |  | 0.93 | 0.72-1.19 | 0.54 |  | 1.01 | | | 0.73-1.39 | | 0.97 |
| **Disease grade, high grade** | |  |  |  | |  |  |  | |  | |  | | | | |  |
| No. with cancer/total\*\*\* | | 122/1,319 | 42/561 | | | |  | 42/496 | | |  | 20/286 | | | | |  |
| Univariable | | Referent | 0.79 | 0.55-1.14 | | 0.22 |  | 0.91 | 0.63-1.31 | 0.60 |  | 0.74 | | | 0.45-1.21 | | 0.22 |
| Multivariable\* | | Referent | 0.68 | 0.45-1.02 | | 0.06 |  | 1.01 | 0.69-1.47 | 0.97 |  | 0.70 | | | 0.41-1.19 | | 0.19 |
| **Dutasteride Arm** | | | | | | | | | | | | | | | | | | |
| **Overall prostate cancer risk** | |  |  |  |  | |  |  |  |  |  |  |  | | |  | |  |
| No. with cancer/total | | 324/1543 |  |  | 129/692 | |  |  |  | 106/578 |  |  |  | | | 62/326 | |  |
| Univariable | | Referent |  | 0.86 | 0.69-1.08 | | 0.20 |  | 0.85 | 0.66-1.08 | 0.17 |  | 0.88 | | | 0.65-1.20 | | 0.42 |
| Multivariable\* | | Referent |  | 0.81 | 0.63-1.05 | | 0.11 |  | 0.87 | 0.67-1.11 | 0.26 |  | 0.86 | | | 0.62-1.19 | | 0.37 |
| **Disease grade, low grade** | |  |  |  |  | |  |  |  |  |  |  |  | | |  | |  |
| No. with cancer/total\*\* | | 213/1,645 |  |  | 82/645 | |  |  |  | 78/656 |  |  |  | | | 38/302 | |  |
| Univariable | | Referent |  | 0.83 | 0.63-1.10 | | 0.19 |  | 0.95 | 0.72-1.25 | 0.70 |  | 0.82 | | | 0.57-1.19 | | 0.30 |
| Multivariable\* | | Referent |  | 0.79 | 0.58-1.06 | | 0.12 |  | 0.98 | 0.74-1.31 | 0.89 |  | 0.82 | | | 0.55-1.21 | | 0.32 |
| **Disease grade, high grade** | |  |  |  |  | |  |  |  |  |  |  |  | | |  | |  |
| No. with cancer/total\*\*\* | | 111/1,330 |  |  | 47/610 | |  |  |  | 28/500 |  |  |  | | | 24/288 | |  |
| Univariable | | Referent |  | 0.92 | 0.64-1.31 | | 0.63 |  | 0.65 | 0.43-0.99 | **0.05** |  | 1.00 | | | 0.63-1.58 | | 0.99 |
| Multivariable\* | | Referent |  | 0.86 | 0.58-1.29 | | 0.47 |  | 0.63 | 0.41-0.99 | **0.043** |  | 0.93 | | | 0.57-1.54 | | 0.79 |
| OR, odds ratio; CI, confidence interval  \*Adjusted for age, race, geographic region, prostate specific antigen levels, prostate volume, digital rectal examination findings, body mass index, treatment arm,  smoking, alcohol, statin use, hypertension, diabetes and cardiovascular disease.  \*\*Numbers reflect men included in the analysis: those with low-grade disease and those without cancer  \*\*\*Numbers reflect men included in the analysis: those with high-grade disease and those without cancer | | | | | | | | | | | | | | | | | | |

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Referent |  | 0.77 | 0.58-1.02 | 0.06 |  | 0.83 | 0.62-1.10 | 0.19 |  | 0.81 | 0.57-1.16 | 0.25 |

**Supplementary Table 2. Association between ASA and/or NSAID use and prostate**

**cancer risk or disease grade vs. non-use stratified by treatment arm**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Non-users** |  | **ASA and/or NSAID users** | | |
| **Variable** |  |  | **OR** | **95% CI** | **p-value** |
| **Placebo Arm** | | | | | |
| **Overall prostate cancer risk** |  |  |  |  |  |
| No. with cancer/total | 429/1,626 |  |  | 386/1,625 |  |
| Univariable | Referent |  | 0.87 | 0.74-1.02 | 0.08 |
| Multivariable\* | Referent |  | 0.88 | 0.74-1.05 | 0.16 |
| **Disease grade, low grade** |  |  |  |  |  |
| No. with cancer/total\*\* | 307/1,504 |  |  | 282/1,521 |  |
| Univariable | Referent |  | 0.88 | 0.77-1.01 | 0.19 |
| Multivariable\* | Referent |  | 0.91 | 0.75-1.11 | 0.35 |
| **Disease grade, high grade** |  |  |  |  |  |
| No. with cancer/total\*\*\* | 122/1,319 |  |  | 104/1,343 |  |
| Univariable | Referent |  | 0.82 | 0.63-1.08 | 0.16 |
| Multivariable | Referent |  | 0.81 | 0.60-1.09 | 0.17 |
|  |  |  |  |  |  |
| **Dutasteride Arm** | | | | | |
| **Overall prostate cancer risk** |  |  |  |  |  |
| No. with cancer/total | 324/1,543 |  |  | 297/1,596 |  |
| Univariable | Referent |  | 0.86 | 0.72-1.03 | 0.09 |
| Multivariable\* | Referent |  | 0.84 | 0.70-1.02 | 0.08 |
| **Disease grade, low grade** |  |  |  |  |  |
| No. with cancer/total\*\* | 213/1,432 |  |  | 198/1,497 |  |
| Univariable | Referent |  | 0.87 | 0.71-1.08 | 0.20 |
| Multivariable\* | Referent |  | 0.87 | 0.70-1.10 | 0.24 |
| **Disease grade, high grade** |  |  |  |  |  |
| No. with cancer/total\*\*\* | 111/1,330 |  |  | 99/1,398 |  |
| Univariable | Referent |  | 0.84 | 0.63-1.11 | 0.22 |
| Multivariable | Referent |  | 0.78 | 0.57-1.07 | 0.12 |

OR, odds ratio

CI, confidence interval

\*Adjusted for age, race, geographic region, prostate specific antigen levels, prostate volume, digital rectal examination findings, body mass index, treatment arm, smoking, alcohol, statin use, hypertension, diabetes and cardiovascular disease.

\*\* Numbers reflect men included in the analysis: those with low-grade disease and those without cancer \*\*\*Numbers reflect men included in the analysis: those with high-grade disease and those without cancer